AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...
EXTON, Pa., June 26, 2018 /PRNewswire/ -- Largely fueled by Genentech's Ocrevus availability, a paradigm shift has occurred in the US multiple sclerosis (MS) market resulting in increased rates of ...
More than 20 years ago, as Jennifer Digmann focused on completing her coursework and graduating from college, she began experiencing numbness in her hands and feet and eventually double vision. After ...
The role of imaging in diagnosing progressive multiple sclerosis (MS) and in assessing prognosis is the subject of a new review. MRI is central in the diagnostic workup of patients suspected of having ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ ...
Symptoms come and go in most cases of multiple sclerosis (MS), a chronic disease in which the immune system attacks myelin, the nonconductive sheath that surrounds neurons' axons. Yet 10 to 15 percent ...
Based on promising results from the Phase 1a study including sustained disability improvements among progressive MS patients, the Phase 1b study will assess clinical outcomes including measures of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback